Navigation Links
Unique genetic marker may improve detection of recurrent ovarian cancer
Date:12/7/2011

Ovarian cancer is a major health concern for women and the identification of sensitive biomarkers for early detection and/or monitoring of disease recurrence is of high clinical relevance.

New work published in the Dec. 7 issue of the online journal PLoS ONE reports promising advances toward the development of blood-based DNA markers for ovarian cancer.

The researchers, led by Peter W. Laird of the University of Southern California in Los Angeles, found that a DNA modification called "methylation" at a specific DNA site occurs frequently in ovarian tumors and can also be detected in the blood of ovarian cancer patients. This newly described methylation site was identified through a rigorous high-throughput screening process that tested over 27,000 different sites in the genome.

The epigenetic marker identified in this study was shown to have the potential to monitor disease status after surgery and might therefore prove helpful in enhancing the performance of existing biomarkers for disease recurrence.


'/>"/>
Contact: Yael Franco
yfranco@plos.org
415-568-3169
Public Library of Science
Source:Eurekalert

Page: 1

Related medicine news :

1. Bariatricfurnishings.com Launches Unique Eco-friendly Seating for Health Care, Hospitality, Assisted Living Centers, and Home Use at Competitive Prices
2. Product Innovators Launch Unique Sensory Tool for Special Needs Youth
3. Beware the Gentle Man With Unique Knowledge: The Passion and Skill of a Rising Star
4. Cloud Computing Platforms Address Unique M2M Application Needs, According To New SensorLogic White Paper
5. UniqueU Medical Weight Loss Program Opens Cincinnati Location
6. Biocell Center Corporation Partners with New Englands Largest Community-Based Hospital Network to Offer a Unique Service in Amniotic Fluid Stem Cell Preservation
7. Unique Equipment, Fun Workouts, Extraordinary Results
8. China VoIP & Digital Telecom Subsidiary, Beijing PowerUnique Technologies, Wins Virtualization Project Bid for Peking Universitys Third Hospital
9. 12 Unique Iridoids Have Been Found in Noni Fruit
10. Unique Alzheimer's Program Improves Quality Of Life And Provides Purpose
11. UniqueU Medical Weight Loss Success Requires an Expansion and Move to a Larger Location
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology: